BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1384@pharmaconomics
DTSTAMP:20260707T031109Z
DTSTART;VALUE=DATE:20260601
DTEND;VALUE=DATE:20260602
SUMMARY:HCM Phase 2 — ORPATHYS
DESCRIPTION:Phase 2 trial results for ORPATHYS in MET-amplified gastric cancer are due Jun 1\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1648257/000164825726000047/hcm-20260702xex99d1.htm\n\nTrack it: https://pharmaconomics.com/e/1384
URL:https://pharmaconomics.com/e/1384
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:HCM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR